Company intelligence / Profile preview

Xinnate

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Xinnate’s lead candidate, TCP‑25 Gel, has demonstrated safety, tolerability, and preliminary efficacy in a completed Phase 1 program involving healthy volunteers with induced wounds and patients with large complex wounds including Epidermolysis Bullosa. The next step is a randomized controlled Phase 2 study in EB patients to further assess safety and efficacy. The company aims to expand the platform into additional indications related to dysfunctional healing.

Therapeutic areas: Dermatology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

tcp-25

Beyond the preview

Go deeper on Xinnate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinnate.

Explore the full profile